Rahul Singhvi Buys Shares of Codexis, Inc.

On June 17, 2026, Rahul Singhvi added 66,350 shares of Codexis, Inc. (NasdaqGS: CDXS) to his holdings. The transaction was recorded at a time when the stock was trading at $2.57.

Other Institutional Activity in Codexis

Aberdeen Group PLC grew its holdings by 713,870 shares, ending with 8,680,368 shares worth about $14.15 million. BlackRock, Inc. reduced its stake by 366,967 shares, leaving it with 7,028,773 shares valued at approximately $11.46 million. Opaleye Management Inc. slightly trimmed its position by 4,738 shares, holding 6,785,000 shares worth $11.06 million. Nantahala Capital Management, LLC increased its position by 133,444 shares, resulting in 4,123,613 shares valued at $6.72 million. Millennium Management LLC added 862,938 shares, bringing its total to 3,998,130 shares worth $6.52 million.

Codexis, Inc. Stock Snapshot

Shares of NasdaqGS:CDXS traded near $2.57. Codexis, Inc. has a market cap of $233.6 million and a beta of 2.478. The stock's 52-week low is $0.96, and its high is $3.87, with a 50-day moving average of $2.57 and a 200-day moving average of $2.02. The company has a current ratio of 5.364 and a quick ratio of 4.927, with a debt-to-equity ratio of 168.624.

Recent Earnings

Codexis, Inc. reported revenue of $78.09 million with a revenue growth rate of 1.021. The company is not currently profitable, with an EPS of -$0.35, a net margin of -40.97%, and a return on equity of -68.90%. The next earnings report is expected on August 12, 2026.

Insider Buying and Selling at Codexis, Inc.

On June 17, 2026, several insiders, including Richards Christos, Parker Stewart, Smith David, Singhvi Rahul, Martinborough Esther, and Dilly Stephen George, each acquired 66,350 shares of Codexis, Inc. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On August 29, 2024, Cantor Fitzgerald reiterated a 'buy' rating with a price target of $11. Stifel Nicolaus maintained a 'buy' rating with a $5 target on May 20, 2024, while Benchmark Co. also maintained a 'buy' rating with a $9 target on May 3, 2024. Piper Sandler reiterated a 'buy' rating with a $10 target on April 26, 2024. The consensus among analysts is a 'buy' recommendation with an average price target of $6.58, based on six analyst opinions.

About Codexis, Inc.

Codexis, Inc. is a biotechnology company based in Redwood City, California. It specializes in creating enzyme-based solutions for therapeutics manufacturing through its CodeEvolver technology platform. The company is involved in developing its ECO Synthesis platform for RNAi therapeutics manufacturing. Codexis collaborates with partners such as Aldevron LLC and Pfizer Inc. Dr. Alison Moore serves as the CEO, leading a team of 146 employees.

Bottom Line

Rahul Singhvi's recent acquisition of Codexis shares highlights ongoing interest in the biotechnology company. Investors often watch insider transactions for potential signals about a company's future, though these actions are not always predictive. With a market cap of $233.6 million and a 'buy' consensus from analysts, Codexis continues to be a point of interest in the healthcare sector.